Optimization of patient selection for gefitinib in non–small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt …
Purpose: Mutations in epidermal growth factor receptor (EGFR) are strongly predictive of
gefitinib efficacy in non–small-cell lung cancer. However, the presence of EGFR mutant …
gefitinib efficacy in non–small-cell lung cancer. However, the presence of EGFR mutant …
Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib
Purpose This study was undertaken to investigate the effects of epidermal growth factor
receptor (EGFR) mutation and its downstream signaling on response and survival in non …
receptor (EGFR) mutation and its downstream signaling on response and survival in non …
Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non–small cell …
TY Chou, CH Chiu, LH Li, CY Hsiao, CY Tzen… - Clinical cancer …, 2005 - AACR
Purpose: Mutations in epidermal growth factor receptor (EGFR) can be used to predict the
tumor response of patients receiving gefitinib for non–small cell lung cancer (NSCLC). We …
tumor response of patients receiving gefitinib for non–small cell lung cancer (NSCLC). We …
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non–small-cell lung cancer
F Cappuzzo, FR Hirsch, E Rossi… - Journal of the …, 2005 - academic.oup.com
Background: Gefitinib is a selective inhibitor of the epidermal growth factor (EGFR) tyrosine
kinase, which is overexpressed in many cancers, including non–small-cell lung cancer …
kinase, which is overexpressed in many cancers, including non–small-cell lung cancer …
[HTML][HTML] Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer
Introduction: We evaluated the efficacy of gefitinib monotherapy prospectively in patients
with advanced or pretreated non-small cell lung cancer (NSCLC) harboring epidermal …
with advanced or pretreated non-small cell lung cancer (NSCLC) harboring epidermal …
Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
R Noro, A Gemma, S Kosaihira, Y Kokubo, M Chen… - BMC cancer, 2006 - Springer
Background Phase III trials evaluating the efficacy of gefitinib (IRESSA) in non-small cell
lung cancer (NSCLC) lend support to the need for improved patient selection in terms of …
lung cancer (NSCLC) lend support to the need for improved patient selection in terms of …
Epidermal growth factor receptor mutations and gene amplification in non–small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials
DW Bell, TJ Lynch, SM Haserlat, PL Harris… - Journal of Clinical …, 2005 - ascopubs.org
Purpose Most cases of non–small-cell lung cancer (NSCLC) with dramatic responses to
gefitinib have specific activating mutations in the epidermal growth factor receptor (EGFR) …
gefitinib have specific activating mutations in the epidermal growth factor receptor (EGFR) …
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non–small-cell lung cancer
FR Hirsch, M Varella-Garcia, PA Bunn Jr… - Journal of clinical …, 2006 - ascopubs.org
Purpose The phase III Iressa Survival Evaluation in Lung Cancer (ISEL) trial compared
gefitinib with placebo in 1,692 patients with refractory advanced non–small-cell lung cancer …
gefitinib with placebo in 1,692 patients with refractory advanced non–small-cell lung cancer …
Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell …
T Sone, K Kasahara, H Kimura, K Nishio… - Cancer, 2007 - Wiley Online Library
BACKGROUND. Because the investigation of epidermal growth factor receptor gene (EGFR)
status as a predictor of gefitinib efficacy in Japanese patients has shown promise, the …
status as a predictor of gefitinib efficacy in Japanese patients has shown promise, the …
Tumor burden is predictive of survival in patients with non–small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib
Background Although activating epidermal growth factor receptor (EGFR) mutations are
excellent predictors of gefitinib outcome in non–small-cell lung cancer (NSCLC), most …
excellent predictors of gefitinib outcome in non–small-cell lung cancer (NSCLC), most …